UBS Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $144M | Sell |
156,288
-82,848
| -35% | -$84M | 0.02% | 787 |
|
|
2025
Q4 | $257M | Sell |
239,136
-46,384
| -16% | -$44.4M | 0.04% | 458 |
|
|
2025
Q3 | $218M | Buy |
285,520
+76,611
| +37% | +$57M | 0.03% | 537 |
|
|
2025
Q2 | $163M | Buy |
208,909
+43,505
| +26% | +$33.8M | 0.03% | 643 |
|
|
2025
Q1 | $137M | Sell |
165,404
-2,990
| -2% | -$2.49M | 0.03% | 719 |
|
|
2024
Q4 | $130M | Sell |
168,394
-17,800
| -10% | -$14.7M | 0.02% | 748 |
|
|
2024
Q3 | $165M | Buy |
186,194
+43,640
| +31% | +$39.2M | 0.04% | 486 |
|
|
2024
Q2 | $129M | Sell |
142,554
-24,346
| -15% | -$19.5M | 0.03% | 519 |
|
|
2024
Q1 | $130M | Sell |
166,900
-50,092
| -23% | -$35.6M | 0.03% | 526 |
|
|
2023
Q4 | $126M | Buy |
216,992
+138,692
| +177% | +$81M | 0.04% | 481 |
|
|
2023
Q3 | $42.1M | Buy |
78,300
+36,800
| +89% | +$19M | 0.01% | 963 |
|
|
2023
Q2 | $19.5M | Buy |
41,500
+4,400
| +12% | +$1.85M | 0.01% | 1472 |
|
|
2023
Q1 | $12.7M | Sell |
37,100
-7,600
| -17% | -$2.56M | ﹤0.01% | 1715 |
|
|
2022
Q4 | $16.4M | Buy |
44,700
+39,700
| +794% | +$14.1M | 0.01% | 1567 |
|
|
2022
Q3 | $1.62M | Buy |
+5,000
| New | +$1.58M | ﹤0.01% | 3342 |
|
|
2022
Q2 | – | Sell |
-28,000
| Closed | -$8.02M | – | 10654 |
|
|
2022
Q1 | $8.02M | Sell |
28,000
-17,896
| -39% | -$4.61M | ﹤0.01% | 2115 |
|
|
2021
Q4 | $12.7M | Sell |
45,896
-25,990
| -36% | -$6.59M | ﹤0.01% | 1942 |
|
|
2021
Q3 | $16.6M | Buy |
71,886
+11,200
| +18% | +$2.76M | 0.01% | 1643 |
|
|
2021
Q2 | $13.9M | Sell |
60,686
-270,700
| -82% | -$54.4M | ﹤0.01% | 1771 |
|
|
2021
Q1 | $61.9M | Buy |
331,386
+233,086
| +237% | +$45.6M | 0.02% | 721 |
|
|
2020
Q4 | $16.6M | Buy |
+98,300
| New | +$14.7M | 0.01% | 1472 |
|
|
2019
Q3 | – | Sell |
-61,300
| Closed | -$6.79M | – | 8132 |
|
|
2019
Q2 | $6.79M | Sell |
61,300
-295,000
| -83% | -$34.7M | ﹤0.01% | 2077 |
|
|
2019
Q1 | $46.2M | Buy |
356,300
+311,300
| +692% | +$37.9M | 0.02% | 673 |
|
|
2018
Q4 | $5.21M | Buy |
+45,000
| New | +$5.03M | ﹤0.01% | 2109 |
|
|
2018
Q3 | – | Sell |
-500
| Closed | -$43K | – | 8128 |
|
|
2018
Q2 | $43K | Buy |
+500
| New | +$41.1K | ﹤0.01% | 6103 |
|
|
2017
Q3 | – | Sell |
-2,300
| Closed | -$189K | – | 7877 |
|
|
2017
Q2 | $189K | Buy |
2,300
+2,000
| +667% | +$163K | ﹤0.01% | 4781 |
|
|
2017
Q1 | $25K | Sell |
300
-802,700
| -100% | -$64.3M | ﹤0.01% | 5991 |
|
|
2016
Q4 | $59.1M | Buy |
803,000
+800,000
| +26,667% | +$59.6M | 0.03% | 474 |
|
|
2016
Q3 | $241K | Sell |
3,000
-40,700
| -93% | -$3.26M | ﹤0.01% | 4424 |
|
|
2016
Q2 | $3.44M | Sell |
43,700
-4,550
| -9% | -$343K | ﹤0.01% | 2313 |
|
|
2016
Q1 | $3.47M | Buy |
48,250
+39,150
| +430% | +$2.96M | ﹤0.01% | 2191 |
|
|
2015
Q4 | $767K | Buy |
9,100
+3,000
| +49% | +$249K | ﹤0.01% | 3610 |
|
|
2015
Q3 | $511K | Sell |
6,100
-400
| -6% | -$33.8K | ﹤0.01% | 3879 |
|
|
2015
Q2 | $543K | Sell |
6,500
-104,500
| -94% | -$7.96M | ﹤0.01% | 4052 |
|
|
2015
Q1 | $8.06M | Buy |
111,000
+46,900
| +73% | +$3.34M | 0.01% | 1645 |
|
|
2014
Q4 | $4.42M | Buy |
+64,100
| New | +$4.33M | ﹤0.01% | 2202 |
|
Other funds holding LLY
VCM
VPM
UBS Group's LLY Position: Q1 2026 in Review
UBS Group increased its Eli Lilly (LLY) stake by 13% in Q1 2026, buying an estimated $486M and bringing the position to 4,043,568 shares worth $3.72B. The position accounts for 0.56% of the portfolio, ranked #16.
UBS Group first reported a position in LLY in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.83B in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- UBS Group held 4,043,568 shares of Eli Lilly worth $3.72B as of Q1 2026.
- UBS Group bought 479,648 Eli Lilly shares in Q1 2026, an estimated $486M.
- Eli Lilly made up 0.56% of UBS Group's portfolio in Q1 2026, its #16 holding.
- UBS Group first reported a position in Eli Lilly in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Eli Lilly position peaked at $3.83B in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.